An agent known as trebananib (formerly AMG386) that binds to both Ang1 and Ang2 and inhibits their interaction with Tie273 has been tested in multiple clinical trials in cancer and has been administered to a fairly large number of patients74,75. Here, ANGPT2 is linked to cancer.